US › Healthcare

Lantern Pharma Inc (LTRN)

US · Healthcare · Biotechnology

$2.75+5.36%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.3M
Profit YoY
+26.6%
EPS
$-0.30
EPS estimate
$-0.36

EPS came in at -0.30 against a street estimate of -0.36 — a beat of 16.7%.

Key statistics

Market cap
$33.6M
Forward P/E
0.0
P/B
9.78
Book value
$0.31
EPS (TTM)
$-1.46
52-week high
$5.74
52-week low
$1.11
50-day MA
$3.45
200-day MA
$3.10
Beta
2.29

Analyst view

Analysts rate Lantern Pharma Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $20.00.

Shareholding

Insiders
20.32%
Institutions
14.22%

Largest institutional holders

FundStake
BIOS CAPITAL MANAGEMENT, LP6.78%
Vanguard Capital Management, LLC2.60%
CM Management, LLC1.96%
Renaissance Technologies Corp0.91%
Geode Capital Management, LLC0.88%
Westside Investment Management, Inc.0.39%
Voss Capital LLC0.39%
Vanguard Fiduciary Trust Co0.39%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lantern Pharma Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.